Core Viewpoint - The company, Hema Medical (03309.HK), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the transaction expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition aims to enhance the company's medical services in Hong Kong and leverage existing patient bases for synergistic effects with its operations in Hong Kong and cross-border business in Shenzhen [1] Group 2: Market Position and Strategy - The company has been actively seeking to expand its market opportunities to meet the demand for high-quality medical services [1] - Hong Kong Endoscopy Centre has a strong reputation in Hong Kong, with advantages in management, quality medical services, and financial performance [1]

Core Viewpoint - The company, Hema Medical (03309), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the acquisition expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers on August 26, 2025 [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition aims to meet the market demand for high-quality medical services and is expected to enhance the company's presence in Hong Kong [1] Group 2: Strategic Rationale - The company believes that Hong Kong Endoscopy Centre has advantages in management, quality medical services, and financial performance [1] - The acquisition is anticipated to create synergies with the company's existing patient base and operations in Hong Kong and Shenzhen [1] - The board of directors considers the acquisition to be in the overall interest of the company and its shareholders [1]

Core Viewpoint - The company, Hema Medical (03309), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the acquisition expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers on August 26, 2025 [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition is anticipated to enhance the company's medical service offerings in Hong Kong and leverage existing patient bases for synergistic effects with its operations in Shenzhen [1] Group 2: Strategic Rationale - The company aims to meet the market demand for high-quality medical services and has been actively exploring potential business opportunities [1] - The board believes that Hong Kong Endoscopy Centre possesses advantages in management, quality medical services, and financial performance, making the acquisition beneficial for the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 C-MER Medical Holdings Limited 希瑪醫療控股有限公司 （股份代號：3309） （於開曼群島註冊成立之有限公司） 自願性公告 收購一間內視鏡中心 本 公 告 由 希 瑪 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出。 – 1 – 為 滿 足 市 場 對 優 質 醫 療 服 務 的 需 求，本 集 團 一 直 致 力 開 拓 潛 在 商 機。香 港 內 視 鏡 中 心 總 部 設 於 香 港，已 有 九 年 營 運 歷 史，是 一 間 在 香 港 具 有 良 好 聲 譽 的 內 視 鏡 中 心。董 事 認 為，香 港 內 視 鏡 中 心 在 管 理、優 質 醫 療 服 務 及 財 務 表 現 方 面 均 具 備 優 勢，此 舉 將 擴 大 本 公 司 在 香 港 ...